Abeona’s Gene Therapy EB-101 Receives FDA’s Regenerative Medicine Advanced Therapy Designation – Epidermolysis Bullosa News
Epidermolysis Bullosa News |
Abeona's Gene Therapy EB-101 Receives FDA's Regenerative Medicine Advanced Therapy Designation
Epidermolysis Bullosa News Abeona Therapeutics' EB-101, a gene therapy in development for patients with recessive dystrophic epidermolysis bullosa (RDEB), has received the regenerative medicine advanced therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA … Abeona Gene Therapy Gains FDA Regenerative Medicine Designation FDA grants RMAT designation for Abeona's gene therapy for epidermolysis bullosa |
